SABR for oligometastatic renal cell carcinoma
Loading...
Citations
Scopus:
Altmetric:
Altmetric::
Download
Associated Records
Authors
File Licence
Editors
Date
2024-03-01
Source Title
Clinical and Translational Radiation Oncology
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
Melbourne Authors
Affiliation
Sir Peter MacCallum Department of Oncology
Document Type
Journal Article
Subject Code
Citation
David, C., Muhammad, A., Cristian, U., Ben, T., Arun, A., Lewis, A., Lavinia, S., Marlon, P. & Shankar, S. (2024). SABR for oligometastatic renal cell carcinoma. Clinical and Translational Radiation Oncology, 45, pp.100739-. https://doi.org/10.1016/j.ctro.2024.100739.
Access Status
Open Access
Access URL
Open Access URL
published version
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Stereotactic ablative body radiotherapy (SABR) aims to accurately deliver a higher than conventional dose of radiotherapy to a well-defined target tumour incorporating advanced immobilisation and imaging techniques. SABR is an emerging treatment option for primary kidney cancer especially when surgery is contraindicated. Increasingly, SABR is being incorporated into the management of low-volume stage IV kidney cancers to delay the need for systemic therapy or to prolong the duration of ongoing systemic treatment. This review will evaluate the evidence and limitations of SABR for oligometastatic renal cell carcinoma.